Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04155996
Other study ID # VTC-MLS-EC01
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date January 20, 2019
Est. completion date December 4, 2020

Study information

Verified date March 2022
Source ValoTec
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this study is to collect continuous glucose monitoring (CGM) data, coupled with physical activity and everyday day life data. The purpose of this data collection is to help diabetologists to make recommendations to optimize type 2 diabetic patient management.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date December 4, 2020
Est. primary completion date December 4, 2020
Accepts healthy volunteers No
Gender All
Age group 35 Years and older
Eligibility Inclusion Criteria: - Type 2 diabetic patient (T2D) with HbA1c = 8% in the month prior to inclusion - Patient is treated with oral anti-diabetics and / or analogous combined with basal insulin therapy (1 injection of slow-acting insulin in the evening) - Age = 35 years - Diabetes diagnosis done over 1 year ago - Patient accepting for 2 periods of 14 days spaced at most 3 days to wear a Freestyle glucose meter, a bracelet for measuring physical activity and to log daily life events in a dedicated smartphone application - Patient is able to use a smartphone - Patient is affiliated to the French health insurance system Exclusion Criteria: - Patient has Type 1 diabetes, diabetes secondary to pancreatic pathology, endocrinopathy or iatrogenic diabetes - Patient is treated with a rapid-acting insulin - Patient has had a severe hypoglycaemia in the year preceding inclusion - Patent has a severe renal insufficiency (defined by a Glomerular Filtration Rate below 30 ml/min) - Patient has had a myocardial infarction or other life-threatening medical condition in the last 6 months - Patient has cognitive disorders or evolutionary psychiatric pathology - Pregnant woman or woman likely to be pregnant, breastfeeding woman - Patient plans to travel outside europe during the study - Patient is participating to another clinical study

Study Design


Intervention

Device:
data collection
Patients will receive a full data acquisition set with CGM sensors, an activity tracker and a smartphone application in which they can log daily events.

Locations

Country Name City State
France GH Pitié Salpêtrière Charles Foix Paris Ile De France

Sponsors (2)

Lead Sponsor Collaborator
ValoTec APHP

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Data collection - Blood glucose levels Patients wear a continuous glucose monitoring patch and record blood glucose level measurements (in mg/dl) over time. 28 days
Primary Data collection - Number of steps Patients wear an activity tracker that will record their number of steps over time. 28 days
Primary Data collection - Sleep hours Patients wear an activity tracker that will record their sleep hours (sleep start time and sleep end time) during nighttime. 28 days
Secondary Data collection - Daily meals information Patients manually record information about meals in a dedicated smartphone application.
Each meal size (Small, Medium or Large) and glycemic index (Low, Medium or High) is evaluated by patients in the application.
28 days
Secondary Data collection - Physical activity information Patients manually record information about physical activities in a dedicated smartphone application.
Each physical activity duration (Short, Medium or Long) and intensity (Low, Medium or High) is evaluated by patients in the application.
28 days
Secondary Data collection - Medical treatment information Patients manually record information their medical treatment in a dedicated smartphone application.
Treatment intake times are recorded in the smartphone application.
28 days
See also
  Status Clinical Trial Phase
Recruiting NCT03239366 - A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population Phase 2
Completed NCT04597229 - Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus N/A
Completed NCT03623139 - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes N/A
Active, not recruiting NCT04599920 - Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life) N/A
Active, not recruiting NCT03422471 - Hypoglycemia and Autonomic Nervous System Function- B2 N/A
Completed NCT04382521 - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions N/A
Recruiting NCT04564391 - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins N/A
Recruiting NCT03458715 - The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Completed NCT02974504 - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN) Phase 4
Completed NCT05053828 - Type 2 Diabetes With Antiplatelet Drugs
Not yet recruiting NCT03659383 - The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine Phase 4
Completed NCT03542240 - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome N/A
Completed NCT03657537 - Effects of Ketone Bodies on Cognition in Type 2 Diabetes Phase 1
Completed NCT03979768 - Risk Assessment of Type 2 Diabetes in Pharmacies N/A
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Active, not recruiting NCT04994288 - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients Phase 2/Phase 3
Completed NCT03290768 - Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3) N/A
Enrolling by invitation NCT04088851 - "The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes" N/A
Completed NCT03643783 - Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients